论文部分内容阅读
目的探讨血清CK19片段检测方法对恶性肿瘤的诊断价值,并与Cyfra21-1进行比较。方法应用CK19-2G2和Cyrfa21-1的检测试剂盒,分别检测恶性肿瘤患者200例(包括肺癌患者51例、胃癌患者34例、膀胱癌患者47例、胰腺癌患者37例、乳腺癌患者31例)、良性病变患者110例和健康者113例。结果恶性肿瘤患者CK19-2G2和Cyfra21-1检测结果均显著高于良性病变患者,差异有统计学意义(P<0.05);良性病变患者CK19-2G2和Cyfra21-1检测结果均显著高于健康者,差异有统计学意义(P<0.05)。CK19-2G2诊断肺癌、膀胱癌、胰腺癌及全部恶性肿瘤的灵敏度要高于Cyfra21-1,差异具有统计学意义(P<0.05)。结论通过ROC曲线分析,CK19-2G2对于恶性肿瘤的诊断准确性要优于Cyfra21-1,2种标志物联合检测的诊断准确性要高于单一标志物检测。CK19-2G2可以作为一种广谱性肿瘤标志物对恶性肿瘤进行辅助诊断。
Objective To investigate the diagnostic value of serum CK19 fragment in malignant tumors and to compare with Cyfra21-1. Methods 200 patients with malignant tumors (including 51 patients with lung cancer, 34 patients with gastric cancer, 47 patients with bladder cancer, 37 patients with pancreatic cancer, 31 patients with breast cancer, CK19-2G2 and Cyrfa21-1 were detected by using the kit of CK19-2G2 and Cyrfa21-1. ), Benign lesions in 110 patients and 113 healthy subjects. Results The results of CK19-2G2 and Cyfra21-1 in malignant tumor patients were significantly higher than those in benign lesions (P <0.05). The results of CK19-2G2 and Cyfra21-1 in patients with benign lesions were significantly higher than those in healthy subjects , The difference was statistically significant (P <0.05). The sensitivity of CK19-2G2 in diagnosing lung cancer, bladder cancer, pancreatic cancer and all malignant tumors was higher than that of Cyfra21-1, with statistical significance (P <0.05). Conclusion According to ROC curve analysis, the diagnostic accuracy of CK19-2G2 is superior to that of Cyfra21-1 in malignant tumors. The diagnostic accuracy of the two markers combined detection is higher than that of single marker detection. CK19-2G2 can be used as a broad-spectrum tumor marker in the diagnosis of malignant tumors.